The Latest Cardiac and Vascular News
September 24, 2024 10:00 AM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Toro Neurovascular, an innovative medical device company, is excited to announce the successful treatment of the first patient using its Toro 88 SuperBore Aspiration Catheter as part of a first-in-man clinical study. The procedure, performed by esteemed neurosurgeon Nobuyuki Sakai, […]
HALETHORPE, Md., Sept. 24, 2024 /PRNewswire/ — Fzata, Inc. is pleased to announce a five-year UG3/UH3 non-dilutive grant (UG3NS135350) of up to $7 million, plus in-kind contributions, awarded by the NIH National Institute of Neurological Disorders and Stroke (NINDS). Grant participants…
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ — Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and…
NANJING, China, Sept. 5, 2024 /PRNewswire/ — On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation…
SUZHOU, China, Aug. 28, 2024 /PRNewswire/ — Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited (“Achieva Medical”),…
Risk Predication Tool, Developed by Anesthesiologists at Montefiore Health System and Albert Einstein College Medicine, May Reduce Adverse Outcomes BRONX, N.Y., Aug. 23, 2024 /PRNewswire/ — A new computational risk assessment prediction tool developed by anesthesiologists at Montefiore…
Gosselies (Belgium), August 21, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies to prevent and treat thrombotic and inflammatory diseases, announces today that the DMC reviewed the data from the first 8 patients in a planned review of the ongoing BIRCH Phase 2a trial of BIOX-101 to prevent secondary damage after intracerebral hemorrhagic stroke (ICH).
FOUNTAIN VALLEY, Calif., Aug. 20, 2024 /PRNewswire/ — MemorialCare’s Long Beach Medical Center and Saddleback Medical Center received the American Heart Association’s Get With The Guidelines® – Stroke Gold Plus quality achievement awards. Long Beach Medical Center also received the Get…
Innovative Collaboration to Enhance Ischemic Stroke Detection and Patient Care, Elevating Standards in Diagnostic Imaging MILAN and SAN DIEGO, July 31, 2024 /PRNewswire/ — Bracco Imaging S.p.A., part of the Bracco Group, a global leader in the field of diagnostic imaging solutions, and…
July 26, 2024 02:00 AM Eastern Daylight Time PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct […]
